Katharina A. Mayer
Vienna, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
T-Cell Engager-Mediated HLA Antibody Depletion before Kidney Transplantation.
Journal: The New England journal of medicine
Published: July 29, 2026
Prolonged CD38 targeting with felzartamab in antibody-mediated kidney transplant rejection: a biomarker-guided open-label phase 2 extension.
Journal: The Lancet regional health. Europe
Published: March 30, 2026
A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation.
Journal: Kidney international
Published: January 23, 2026
Early Acute T Cell-Mediated Rejection and Kidney Allograft Outcomes.
Journal: Kidney international
Published: February 24, 2025
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation.
Journal: Expert opinion on investigational drugs
Published: February 10, 2025
Targeting CD38 in Antibody-Mediated Rejection.
Journal: Transplant international : official journal of the European Society for Organ Transplantation
Published: January 14, 2025
Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study.
Journal: Transplantation
Published: October 15, 2024
Estimating the efficacy of felzartamab to treat antibody-mediated rejection using the iBox prognostication system.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: October 07, 2024
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
Journal: The New England journal of medicine
Published: May 28, 2024
Last Updated: 09/26/2026